KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC Melanoma
KEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III Disease
https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-231500886.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.